• Thumbnail for Biogen
    Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development...
    48 KB (3,837 words) - 18:51, 12 September 2024
  • Biogen (UK) Ltd is a leading UK owner and operator of anaerobic digestion and composting plants based in Bedfordshire. It is responsible for the construction...
    5 KB (502 words) - 19:52, 6 December 2024
  • people with Alzheimer's disease to reduce its buildup. It was developed by Biogen and Eisai. Aducanumab is given via intravenous infusion. Aducanumab was...
    61 KB (4,888 words) - 02:50, 17 November 2024
  • Thumbnail for Nusinersen
    funded by Cure SMA. Starting in 2012, Ionis partnered with Biogen on development and, in 2015, Biogen acquired an exclusive license to the drug for a US$75...
    27 KB (2,095 words) - 15:28, 26 September 2024
  • Thumbnail for Multiple sclerosis
    S2CID 46326042. "Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US as a First-Line Oral Treatment for Multiple Sclerosis" (Press release). Biogen Idec....
    173 KB (18,317 words) - 15:53, 28 December 2024
  • Thumbnail for Fumaric acid
    esters, primarily dimethyl fumarate, and marketed as Fumaderm by Biogen Idec in Europe. Biogen would later go on to develop the main ester, dimethyl fumarate...
    12 KB (967 words) - 06:20, 2 January 2025
  • T-cells. In March 2018, it was voluntarily withdrawn from the market by Biogen and Abbvie after reports of autoimmune encephalitis in Europe. Daclizumab...
    18 KB (1,656 words) - 19:23, 6 November 2024
  • Thumbnail for Bill Anderson (businessman)
    a marketing manager for Raychem. From 1997 to 2006, Anderson worked at Biogen in multiple countries, including, Ireland, the U.S., and the U.K., holding...
    7 KB (608 words) - 07:21, 23 May 2024
  • Thumbnail for Samsung
    Biologics (50 per cent plus one share) and the U.S.-based Biogen Idec (50 per cent). In 2014, Biogen Idec agreed to commercialize future anti-TNF biosimilar...
    139 KB (12,974 words) - 09:56, 21 December 2024
  • Thumbnail for Tofersen
    developed by Ionis Pharmaceuticals and was licensed to, and co-developed by, Biogen. The effectiveness of tofersen was evaluated in a 28-week, randomized, double-blind...
    12 KB (860 words) - 04:18, 7 September 2024
  • as CEO between 2021 and 2022. He was formerly the president and CEO of Biogen Idec until he retired effective June 8, 2010. At the same time, he started...
    5 KB (533 words) - 08:46, 28 September 2024
  • Thumbnail for Dimethyl fumarate
    conducted by Fumapharm in collaboration with Biogen Idec; Fumapharm was subsequently acquired by Biogen Idec in 2006. Aditech Pharma in Sweden had also...
    30 KB (2,897 words) - 14:05, 20 July 2024
  • Tools & Services Minneapolis, Minnesota 2021-08-30 0000842023 1976 BIIB Biogen Health Care Biotechnology Cambridge, Massachusetts 2003-11-13 0000875045...
    198 KB (6,428 words) - 04:36, 26 December 2024
  • Thumbnail for Massachusetts
    Tower, Global Partners, Thermo Fisher Scientific, State Street Corporation, Biogen, Eversource Energy, and Boston Scientific. CNBC's list of "Top States for...
    254 KB (22,105 words) - 01:11, 30 December 2024
  • Thumbnail for Cambridge, Massachusetts
    regulations in 1977. This led to regulatory certainty and acceptance when Biogen opened a lab in 1982, in contrast to the hostility that caused the Genetic...
    166 KB (13,714 words) - 22:00, 28 December 2024
  • Thumbnail for William Rastetter
    merged with Biogen to form the third largest biotech firm in the United States. Rastetter was Executive Chair of the new company, Biogen IDEC, from 2003...
    28 KB (2,562 words) - 22:43, 28 December 2024
  • antibodies targeting amyloid. Lecanemab was jointly developed by Eisai and Biogen. It was granted accelerated approval for medical use in the United States...
    30 KB (2,672 words) - 07:01, 6 December 2024
  • Thumbnail for Ionis Pharmaceuticals
    initially developed by Ionis, which partnered with Biogen on development starting in 2012; in 2015 Biogen acquired an exclusive license to the drug for a...
    18 KB (1,649 words) - 22:39, 28 December 2024
  • Cambridge, Massachusetts-headquartered multinational biotechnology company, Biogen for nearly $6.5 billion. The purchase was completed on September 26 and...
    10 KB (958 words) - 07:23, 9 May 2024
  • Thumbnail for Interferon beta-1a
    around 30% of the overall market.[citation needed] It is produced by the Biogen biotechnology company, originally under competition protection in the US...
    32 KB (2,851 words) - 23:22, 16 August 2024
  • from 2017 to 2023. Scangos was previously the chief executive officer of Biogen from 2010 to 2016 and of Exelixis from 1996 to 2010. Prior to joining industry...
    8 KB (686 words) - 01:16, 18 September 2024
  • Thumbnail for Greater Boston
    (headquarters) Biocell Center, in Medford (North American headquarters) Biogen Idec, in Weston (North American headquarters) Carl Zeiss SMT, in Peabody...
    73 KB (3,422 words) - 14:37, 11 December 2024
  • the PCT. "Biogen Reports Top-Line Results from Phase 2 Study of Opicinumab (Anti-LINGO-1) in Multiple Sclerosis | Biogen Media". media.biogen.com. Retrieved...
    8 KB (838 words) - 16:18, 2 November 2023
  • L. "Jim" Vincent (1940 – December 5, 2013) was the chairman and CEO of Biogen Idec from 1985 to 2002. He graduated from Duke University's Pratt School...
    6 KB (634 words) - 15:17, 26 July 2024
  • "a polyethylene glycol conjugated anti-CD40L Fab fragment" developed by Biogen for systemic lupus erythematosus. Chamberlain, Chris; Colman, Peter J; Ranger...
    2 KB (222 words) - 23:44, 17 July 2024
  • Thumbnail for Élan
    February 2013, Elan decided to dispose of the rights to sell Tysabri to Biogen Idec for $3.25 billion. In neurology, Elan was focused on building upon...
    7 KB (530 words) - 16:41, 3 January 2024
  • Thumbnail for SAGE-324
    receptor positive allosteric modulator. SAGE-324 was being developed by Biogen for the treatment of essential tremor. Its development was discontinued...
    6 KB (296 words) - 12:21, 24 July 2024
  • Thumbnail for Rituximab
    Health Organization's List of Essential Medicines. Rituxan is co-marketed by Biogen and Genentech in the US, by Roche elsewhere except Japan, and co-marketed...
    63 KB (5,701 words) - 19:01, 23 December 2024
  • Thumbnail for Osteopathy
    Thorax; VII. The Diaphragm; VIII. The Abdomen; IX. The Pelvis; X. Fevers; XI. Biogen; XII. Smallpox; XIII. Obesity; XIV. Ear-Wax and Its Uses; XV. Convulsions;...
    76 KB (8,021 words) - 08:46, 27 August 2024
  • 2016 Biogen announced that it would spin off its hemophilia drug business (Eloctate and Alprolix) into a separate public company. In August, Biogen announced...
    7 KB (469 words) - 20:41, 2 December 2024